FLY Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of January 12, 2026 Deadline in Securities Fraud Class Action Lawsuit Against Firefly Aerospace Inc. (FLY)

The law firm of Kessler Topaz Meltzer & Check, LLPinforms investors that a securities class action lawsuit has been filed against Firefly Aerospace Inc. (“Firefly”) (NASDAQ: FLY) on behalf of those who purchased or otherwise acquired Firefly: (1) common stock pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued […]

SFM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sprouts Farmers Market, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announces that purchasers of Sprouts Farmers Market, Inc. (NASDAQ: SFM) securities between June 4, 2025 and October 29, 2025, both dates inclusive (the “Class Period”), including sellers of put options, have until January 26, 2026 to seek appointment as lead plaintiff of the Sprouts class action lawsuit. CaptionedSingh Family

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

(HKSE:6855),(NasdaqGM:AAPG), Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment option Lisaftoclax achieved a 62.5% objective response rate (ORR) in heavily pretreated, BTKi-refractory patients, nearly half with complex karyotype Lisaftoclax monotherapy demonstrated a median progression-free

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting GlobeNewswire December 06, 2025 Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Logitech International S.A. – LOGI

NEW YORK, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Logitech International S.A. ("Logitech" or the "Company") (NASDAQ:LOGI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Logitech and certain of its officers and/or directors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited – RGC

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ:RGC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Regencell and certain of its officers

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Plug Power Inc. – PLUG

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Plug Power Inc. ("Plug" or the "Company") (NASDAQ:PLUG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Plug and certain of its officers and/or

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. – OM

NEW YORK CITY, NY / ACCESS Newswire / December 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ:OM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Outset Medical and certain of its

JCBC Publishing, LLC Announces Launch of ‘That Kind of Girl,’ Jacey Bici’s Debut Novel, in 2025

JCBC Publishing, LLC Announces Launch of 'That Kind of Girl,' Jacey Bici's Debut Novel, in 2025 Celebrated physician and author Jacey Bici unveils her first women's fiction novel, exploring transformative moments in women's lives. GlobeNewswire December 06, 2025 Lakewood Ranch, Dec. 06, 2025 (GLOBE NEWSWIRE) — JCBC Publishing, LLC, a distinguished name in the literary

Scroll to Top